Skip to main content
. 2022 Dec 12;7(1):24–37. doi: 10.1038/s41551-022-00969-0

Extended Data Fig. 7. CAR overexpression did not show distinctive enhancement of iCAR-TCTL therapy.

Extended Data Fig. 7

a. Transgene marker expression of iCAR-TCTL and CAR-o/e-iCAR-TCTL b. Surface antigen profiles of iCAR-TCTL and CAR-o/e-iCAR-TCTL. iCAR-TCTL and CAR-o/e-iCAR-TCTL were evaluated using surface antigen expression related to T/NK linage, naïve/memory, and exhaustion phenotype. c-d. Detection of phosphorylated ERK (pERK) in iCAR-TCTL and CAR-o/e-iCAR-TCTL 60 min after co-culturing with irradiated SK-Hep-GPC3 e. In vitro cytotoxic assays of iCAR-TCTL and CAR-o/e-iCAR-TCTL against JHH7 and SK-Hep-GPC3. n = 4, mean ± SD. f. proliferation assay of iCAR-TCTL and CAR-o/e-iCAR-TCTL. g. Cytokine production of iCAR-TCTL and CAR-o/e-iCAR-TCTL cells 48 h after co-culturing with irradiated SK-Hep-GPC3 (n = 4, mean ± SEM). Student’s t-test.